This is a StreetInsider.com Premium Only Page

OPKO Health (OPK) – Globe Newswire

Mar 20, 2024 08:00 AM Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome

Mar 5, 2024 08:52 AM AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV

Feb 27, 2024 04:05 PM OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results

Feb 22, 2024 04:05 PM OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024

Jan 9, 2024 04:05 PM OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser’s Option to Purchase Additional Notes

Jan 8, 2024 08:00 AM OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Jan 4, 2024 11:31 PM OPKO Health Announces Pricing of Private Offering of $200 Million Convertible Senior Notes Due 2029

Jan 3, 2024 05:05 PM OPKO Health Announces Private Offering of Convertible Senior Notes Due 2029

Nov 6, 2023 04:05 PM OPKO Health Reports Third Quarter 2023 Business Highlights and Financial Results

Nov 2, 2023 10:00 AM New Clinical Data on OPKO Health’s RAYALDEE® (ER Calcifediol) Presented at Kidney Week 2023

Oct 31, 2023 08:00 AM OPKO Health to Report Third Quarter 2023 Financial Results on November 6, 2023

Oct 25, 2023 04:25 PM OPKO Health to Present New Clinical Data on Rayaldee (ER Calcifediol) at Kidney Week 2023

Sep 28, 2023 04:08 PM ModeX Therapeutics Secures BARDA Contract to Develop Novel Multispecific Antibodies Against Viral Infectious Disease Threats

Sep 12, 2023 08:30 AM Entera Bio Announces Collaboration with OPKO Biologics to Develop Oral Peptide Tablet Formulations for Obesity and Intestinal Malabsorption Syndromes

Aug 3, 2023 04:05 PM OPKO Health Reports Second Quarter 2023 Business Highlights and Financial Results

Jul 25, 2023 04:05 PM OPKO Health to Report Second Quarter 2023 Financial Results on August 3, 2023

May 3, 2023 04:05 PM OPKO Health Reports First Quarter 2023 Business Highlights and Financial Results

Apr 25, 2023 04:05 PM OPKO Health to Report First Quarter 2023 Financial Results on May 3, 2023

Mar 9, 2023 08:00 AM OPKO Health to Hold Virtual R&D Day on March 20, 2023

Mar 8, 2023 08:00 AM OPKO Health’s ModeX Therapeutics Enters into Exclusive Worldwide License and Collaboration Agreement with Merck to Develop Epstein-Barr Virus Vaccine Candidate

Feb 23, 2023 04:05 PM OPKO Health Reports Fourth Quarter 2022 Business Highlights and Financial Results

Feb 16, 2023 11:41 AM OPKO Health to Report Fourth Quarter 2022 Financial Results on February 23, 2023

Jan 3, 2023 08:00 AM OPKO Health to Present at the 41st Annual J.P. Morgan Healthcare Conference

Nov 8, 2022 04:05 PM OPKO Health Reports Third Quarter 2022 Business Highlights and Financial Results

Nov 1, 2022 08:00 AM OPKO Health to Report Third Quarter 2022 Financial Results on November 8, 2022

Sep 15, 2022 04:05 PM Jon Cohen and Michael Hansen Join Talkspace’s Board of Directors

Sep 15, 2022 04:05 PM Jon Cohen and Michael Hansen Join Talkspace’s Board of Directors

Aug 16, 2022 04:29 PM OPKO Health Announces Leadership Changes for BioReference Laboratories

Aug 4, 2022 04:05 PM OPKO Health Reports 2022 Second Quarter Business Highlights and Financial Results

Jul 25, 2022 04:05 PM OPKO Health to Report Second Quarter 2022 Financial Results on August 4, 2022

Jun 2, 2022 08:00 AM OPKO Health to Present at the 2022 Jefferies Healthcare Conference

May 9, 2022 04:05 PM OPKO Health Reports 2022 First Quarter Business Highlights and Financial Results

May 9, 2022 09:23 AM OPKO Health Acquires ModeX Therapeutics, Gains Proprietary Immunotherapy Technology with a Focus on Oncology and Infectious Diseases

May 5, 2022 04:05 PM OPKO Health to Report First Quarter 2022 Financial Results on May 9, 2022

May 2, 2022 07:45 AM Sema4 Announces the Completion of the GeneDx Acquisition and a Streamlined Leadership Structure to Accelerate Growth of its Diagnostic and Clinical Data Platforms

Feb 24, 2022 04:05 PM OPKO Health Reports 2021 Fourth Quarter Business Highlights and Financial Results

Feb 17, 2022 08:00 AM OPKO Health to Report Fourth Quarter 2021 Financial Results on February 24, 2022

Feb 3, 2022 08:30 AM RAYALDEE® Launched in Germany by OPKO Health’s Licensee, VFMCRP

Jan 20, 2022 08:00 AM Japan’s MHLW Approves Pfizer and OPKO’s NGENLA® (Somatrogon), a New Long-Acting Treatment for Pediatric Growth Hormone Deficiency

Jan 18, 2022 07:00 AM Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform

Jan 18, 2022 07:00 AM Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform

Dec 23, 2021 08:00 AM OPKO Health Announces Topline Results from Phase 2 Trial Evaluating RAYALDEE to Treat Symptomatic COVID-19 Outpatients

Dec 8, 2021 08:00 AM OPKO Health Receives U.S. FDA Approval for the 4Kscore® Test

Dec 6, 2021 08:00 AM OPKO Health Announces the Passing of Director Dr. Richard Lerner

Nov 29, 2021 08:00 AM OPKO Health Announces Participation in Piper Sandler 33rd Annual Virtual Healthcare Conference

Oct 28, 2021 04:15 PM OPKO Health Reports 2021 Third Quarter Business Highlights and Financial Results

Oct 25, 2021 10:57 AM OPKO Health to Report Third Quarter 2021 Financial Results on October 28, 2021

Oct 12, 2021 08:00 AM Krystal Biotech and GeneDx Announce Collaboration to Provide No-charge Genetic Testing for Patients with Suspected Dystrophic Epidermolysis Bullosa (DEB)

Sep 24, 2021 04:24 PM Pfizer and OPKO Announce Extension of U.S. FDA Review of Biologics License Application of Somatrogon for Pediatric Growth Hormone Deficiency

Sep 14, 2021 08:00 AM LeaderMed Group and OPKO Health Form Joint Venture to Develop and Commercialize Oxyntomodulin and Factor VIIa-CTP in China and Other Asian Territories